Adult & adolescent (at least 40 kg)HIV-1 infection not resistant to integrase inhibitors 50 mg once daily. AdultHIV-1 infection known or suspected to be resistant to integrase inhibitors 50 mg bid. In combination w/ efavirenz, nevirapine, tipranavir/ritonavir, or rifampicin 50 mg bid. Childn over 6 yr 1 mg/kg.
Discontinue immediately if hypersensitivity reactions develop. May reduce the risk of sexual transmission but not eliminated entirely. Reduced activity for viral strains w/ Q148 + ≥2 secondary mutations from G140A/C/S, E138A/K/T, L74I. Uncertain efficacy when used to treat HIV-1 w/ type of resistance to integrase inhibitors. Inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise in patients w/ severe immune deficiency & may cause serious clinical conditions or aggravation of symptoms. Autoimmune disorders (eg, Graves' disease). Patient may still develop opportunistic infection & other HIV infection complications. Osteonecrosis in patients w/ advanced HIV disease or following long-term combination therapy. Monitor liver function in patients w/ hepatitis B or C co-infection. Severe hepatic impairment (Child-Pugh grade C). Pregnancy & lactation. Childn <6 yr. Elderly ≥65 yr.
Sign Out
